Summary

Eligibility
for males (full criteria)
Location
at UCLA
Dates
study started
completion around
Principal Investigator
by Johannes Czernin, MD (ucla)
Headshot of Johannes Czernin
Johannes Czernin

Description

Summary

This clinical trial studies mechanisms of resistance to 177-lutetium prostate specific membrane antigen (177Lu-PSMA) radioligand therapy using image-guided biopsies in patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic). Diagnostic procedures, such as image guided biopsies, may help in learning how well 177Lu-PSMA works to kill tumor cells and allow doctors to plan better treatment.

Official Title

Radiologically Guided Biopsies of Metastatic Castration Resistant Prostate Cancer to Identify Mechanisms of Resistance in Patients Undergoing 177Lu-PSMA Radioligand Therapy

Details

Keywords

Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Carcinoma, Prostatic Neoplasms, Image Guided Biopsy

Eligibility

Location

  • UCLA / Jonsson Comprehensive Cancer Center accepting new patients
    Los Angeles California 90095 United States

Lead Scientist at University of California Health

  • Johannes Czernin, MD (ucla)
    Department Vice Chair, Molecular and Medical Pharmacology, Medicine. Authored (or co-authored) 345 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Jonsson Comprehensive Cancer Center
ID
NCT05398302
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 30 study participants
Last Updated